| |
|
|
|
Xtalks, Online
2024-10-30
Real-world data have become an essential resource for life sciences companies working across the product life cycle. But, mounting financial pressures in the industry have led to heightened scrutiny around these investments. The difficulty that many organizations face in effectively communicating the impact of these data and their outputs only compounds the problem.
It is crucial for leaders to articulate the value of these data across the enterprise, demonstrating their impact on the business and advocating for continued investment. With industry dynamics such as evolving regulatory requirements, highly competitive therapeutic markets and the rise of precision medicine, data and evidence are more crucial than ever before to produce high-quality research and meet organizational goals.
In this webinar, speakers specializing in real-world evidence will discuss the current challenges and opportunities in determining the value of real-world data. They will explore strategies for framing the value narrative within an organization and provide vital insights for success.
Register for this webinar today to gain insights into how to effectively communicate the value of real-world data investments across biopharmaceutical organizations.
Keywords: Real-World Data, Real-World Evidence, Clinical Data, Regulatory, HEOR, RWE, Health Economics Outcomes Research, Data Science, Commercialization/HEOR/Market Access, RWD
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Eric Fontana, Vice President, Client Solutions, Real-World Data and Analytics, Optum Life Sciences
Ami Buikema, MPH, Vice President, HEOR Research, Consulting and Client Engagement, Optum Life Sciences
Liz Poole, PhD, Head, Real-World Evidence, Epidemiology, Medical Affairs and Value Statistics (REM), Jazz Pharmaceuticals
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-10-30
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|